Without delving into line items, it's reasonable to assume that rebalancing costs in relation to the generic division would be trailing. Gross profit fall of 9% was more or less in line with the 8% revenue decline, so again, not unexpected in a rebalancing. Clearly the women's health segment will grow substantially from now to become equal to or larger than dermatology.
MYX Price at posting:
28.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)